1,289 results on '"Tahara M"'
Search Results
2. Influencia del realce de contraste al inyectar un medio de contraste en el brazo o la pierna en pacientes neonatos y lactantes durante la angiografía por cardiotomografía
3. Effect of injection duration on contrast enhancement during cardiac computed tomography angiography in newborns and infants
4. Efficacy of the spiral flow generating extended tube during paediatric CCTA
5. Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck
6. Health-Related Quality of Life (HRQoL) Data From KEYNOTE-412: Chemoradiotherapy (CRT) with or Without Pembrolizumab (pembro) in Patients (pts) with Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
7. Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study
8. Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
9. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
10. Global structure of isothermal X-ray emission along the Fermi bubbles
11. Fermi-LAT and Multi-wavelength Monitoring of the Broad Line Radio Galaxy 3C 120
12. Suzaku X-ray Observations of the Fermi Bubbles: Northernmost Cap and Southeast Claw Discovered with MAXI-SSC
13. Six Years of Fermi-LAT and Multi-wavelength Monitoring of the Broad-Line Radio Galaxy 3C 120: Jet Dissipation at Sub-parsec Scales from the Central Engine
14. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
15. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial †
16. 106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study
17. Suzaku observations of the diffuse x-ray emission across the fermi bubbles' edges
18. Multiband Diagnostics of Unidentified 1FGL Sources with Suzaku and Swift X-ray Observations
19. Low Temperature Gas Carburising for Austenitic Stainless Steels: The NV-Pionite Process
20. Developing Transposable Element Marker System for Molecular Breeding
21. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
22. The ward technique for anterior placenta previa
23. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit
24. Effect of Sn Content on Phase Constitution and Mechanical Properties of Ti-Cr-Sn Shape Memory Alloys
25. Deformation Behavior of Ti-4Au-5Cr-8Zr Superelastic Alloy With or Without Containing Ti3Au Precipitates
26. The Effect of Aging Temperature on Morphology of α Phase in Ti-3Mo-6Sn-5Zr Shape Memory Alloy
27. Preferential Morphology of Self-accommodation Microstructure in Ti-Ni-Pd Shape Memory Alloy
28. 222O Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
29. LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)
30. 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048
31. 667P Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
32. 520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358
33. 945TiP JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
34. 944TiP Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1–positive head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial
35. 851MO Final analysis of a phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck (JCOG1008)
36. 849O Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer: Results from the MYTHOS trial
37. 628P Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
38. Optical properties of ZnO thin films grown on glass substrates using catalytically generated high-temperature H2O
39. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
40. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
41. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
42. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.
43. T‐bet over‐expression regulates aryl hydrocarbon receptor‐mediated T helper type 17 differentiation through an interferon (IFN)γ‐independent pathway
44. RORγt antagonist suppresses M3 muscarinic acetylcholine receptor‐induced Sjögrenʼs syndrome‐like sialadenitis
45. Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy
46. A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36)
47. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
48. XRay Vision: A Phase 3 Study of Xevinapant Plus Radiotherapy (RT) for High-risk, Cisplatin-ineligible Patients with Resected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN)
49. Supplement to: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
50. Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.